GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to participate in the 2025 BIO International Convention, the largest global gathering for the biotechnology industry. This event, taking place in Boston, Massachusetts, from June 16-19, 2025, offers GeoVax a platform to engage with potential partners, investors, and policymakers. The company plans to discuss its innovative pipeline, including GEO-MVA for Mpox and smallpox, GEO-CM04S1 for COVID-19, and Gedeptin® for solid tumors.
The significance of GeoVax's participation lies in its potential to forge strategic partnerships and expand manufacturing capabilities, aligning with global priorities in pandemic preparedness, oncology, and biodefense. The company's focus on developing vaccines for immunocompromised patients and more durable COVID-19 boosters addresses critical gaps in current healthcare solutions. GeoVax's advancements in oncology, particularly its Gedeptin® therapy for head and neck cancers, represent a promising direction in cancer treatment.
This announcement underscores the importance of biotechnology innovations in addressing pressing health challenges. GeoVax's efforts could lead to breakthroughs in vaccine development and cancer therapy, offering hope for improved treatments and pandemic preparedness worldwide.
